Healthcare
Thursday, February 2, 2017
BRIEF-Nabriva Therapeutics anticipate topline data from phase 3 trials in second half of 2017
* Nabriva therapeutics confirms no sample size adjustment
required for leap 1 phase 3 trial of lefamulin in community
acquired bacterial pneumonia
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment